GB201800736D0 - Combination therapy for treatment of leukemia - Google Patents

Combination therapy for treatment of leukemia

Info

Publication number
GB201800736D0
GB201800736D0 GBGB1800736.9A GB201800736A GB201800736D0 GB 201800736 D0 GB201800736 D0 GB 201800736D0 GB 201800736 A GB201800736 A GB 201800736A GB 201800736 D0 GB201800736 D0 GB 201800736D0
Authority
GB
United Kingdom
Prior art keywords
leukemia
treatment
combination therapy
therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1800736.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City St Georges University of London
Original Assignee
St Georges Hospital Medical School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Georges Hospital Medical School filed Critical St Georges Hospital Medical School
Priority to GBGB1800736.9A priority Critical patent/GB201800736D0/en
Publication of GB201800736D0 publication Critical patent/GB201800736D0/en
Priority to EP19701714.8A priority patent/EP3740215A1/en
Priority to JP2020539240A priority patent/JP2021510715A/ja
Priority to CN201980017188.1A priority patent/CN111818930A/zh
Priority to US16/962,494 priority patent/US11400112B2/en
Priority to PCT/GB2019/050124 priority patent/WO2019141988A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1800736.9A 2018-01-17 2018-01-17 Combination therapy for treatment of leukemia Ceased GB201800736D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB1800736.9A GB201800736D0 (en) 2018-01-17 2018-01-17 Combination therapy for treatment of leukemia
EP19701714.8A EP3740215A1 (en) 2018-01-17 2019-01-17 Combination therapy for treatment of leukemia
JP2020539240A JP2021510715A (ja) 2018-01-17 2019-01-17 白血病治療のための併用療法
CN201980017188.1A CN111818930A (zh) 2018-01-17 2019-01-17 用于治疗白血病的联合疗法
US16/962,494 US11400112B2 (en) 2018-01-17 2019-01-17 Combination therapy for treatment of leukemia
PCT/GB2019/050124 WO2019141988A1 (en) 2018-01-17 2019-01-17 Combination therapy for treatment of leukemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1800736.9A GB201800736D0 (en) 2018-01-17 2018-01-17 Combination therapy for treatment of leukemia

Publications (1)

Publication Number Publication Date
GB201800736D0 true GB201800736D0 (en) 2018-02-28

Family

ID=61256143

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1800736.9A Ceased GB201800736D0 (en) 2018-01-17 2018-01-17 Combination therapy for treatment of leukemia

Country Status (6)

Country Link
US (1) US11400112B2 (https=)
EP (1) EP3740215A1 (https=)
JP (1) JP2021510715A (https=)
CN (1) CN111818930A (https=)
GB (1) GB201800736D0 (https=)
WO (1) WO2019141988A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269355A (zh) * 2019-05-21 2022-04-01 麦德赛尼克公司 金属离子增强砷的治疗作用的用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3868372A1 (en) * 2020-02-19 2021-08-25 JLP Health GmbH A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer
US11583552B2 (en) 2021-02-17 2023-02-21 Manoj Maniar Pharmaceutical formulation of arsenic trioxide
CN116687965A (zh) * 2023-05-05 2023-09-05 杭州市西溪医院 一种三氧化二砷-青蒿琥酯抗肿瘤组合物、双载药纳米脂质体及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04273819A (ja) * 1991-02-28 1992-09-30 Takeda Chem Ind Ltd 血圧上昇剤
CN1044559C (zh) 1995-08-23 1999-08-11 哈尔滨医科大学附属第一医院 抗白血病、肝癌、淋巴瘤注射液
TR200002243T2 (tr) * 1997-11-10 2000-12-21 Memorial Sloan-Kettering Cancer Center Arsenik trioksitin hazırlanması için işlem ve bunların kanser tedavisi için kullanımı.
CA2488347A1 (en) * 2002-06-06 2003-12-18 University Of Washington Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer
JP2008201765A (ja) * 2007-01-26 2008-09-04 Jichi Medical Univ 腫瘍治療における三酸化二ヒ素の副作用低減剤及び解毒剤
CN102614168A (zh) * 2011-01-31 2012-08-01 上海交通大学医学院附属瑞金医院 一种青蒿素衍生物及其药用盐的应用
CN103202835B (zh) 2012-01-16 2015-05-13 上海交通大学医学院附属瑞金医院 青蒿素衍生物及其药用盐用于制备治疗急性白血病的药物
CN103202836B (zh) 2012-01-16 2015-05-13 上海交通大学医学院附属瑞金医院 青蒿素衍生物及其药用盐用于制备治疗急性髓细胞性白血病的药物
CN103202837B (zh) 2012-01-16 2015-05-13 上海交通大学医学院附属瑞金医院 青蒿素衍生物及其药用盐用于治疗制备白血病的药物
US9801851B2 (en) 2012-05-23 2017-10-31 St. Jude Children's Research Hospital Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias
CN103845322A (zh) 2012-11-29 2014-06-11 昆明制药集团股份有限公司 蒿甲醚在制备治疗白血病的药物中的用途
CN103845360A (zh) * 2012-11-29 2014-06-11 昆明制药集团股份有限公司 含蒿甲醚的药物组合物、制剂及其用途
CN104739824A (zh) 2013-12-30 2015-07-01 昆山达人生物医药有限公司 双氢青蒿素在制备抑制肿瘤生长药物中的应用
EP3233918A1 (en) * 2014-12-19 2017-10-25 Novartis AG Combination therapies
US9918972B2 (en) 2014-12-23 2018-03-20 The University Of Maryland, Baltimore Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents
US10925963B2 (en) 2015-06-22 2021-02-23 Washington University Combination artemisinin and chemiluminescent photodynamic therapy and uses therefor

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269355A (zh) * 2019-05-21 2022-04-01 麦德赛尼克公司 金属离子增强砷的治疗作用的用途
CN114269355B (zh) * 2019-05-21 2023-08-15 麦德赛尼克公司 金属离子增强砷的治疗作用的用途
CN117085038A (zh) * 2019-05-21 2023-11-21 麦德赛尼克公司 金属离子增强砷的治疗作用的用途

Also Published As

Publication number Publication date
JP2021510715A (ja) 2021-04-30
US20200345770A1 (en) 2020-11-05
WO2019141988A1 (en) 2019-07-25
EP3740215A1 (en) 2020-11-25
CN111818930A (zh) 2020-10-23
US11400112B2 (en) 2022-08-02

Similar Documents

Publication Publication Date Title
IL290149A (en) Combined treatment for cancer
IL276398A (en) Combined treatment for mastocytosis
IL267795A (en) Combined treatment for cancer
SG11202104923YA (en) Pharmaceutical combination for treatment of cancer
IL256224B (en) Combined therapy for cancer treatment
IL258521A (en) Combination of treatments for cancer treatment
GB201804514D0 (en) Treatment of pyroptosis
EP3534923A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF BRAIN CARCINOMAS
ZA202206743B (en) Therapy for the treatment of cancer
IL280337A (en) LAG-3 combination therapy for cancer treatment
SG11202011117VA (en) Treatment of cancer
IL261195B (en) Combined treatment for ovarian cancer
EP3629774A4 (en) COMBINATION THERAPY FOR TREATMENT OF RESTENOSIS
IL282643A (en) Soft combinations for the treatment of hematological diseases
SG11202103141YA (en) Combination therapy for the treatment of cancer
IL263905A (en) Combined cancer treatment
GB201804515D0 (en) Treatment of necroptosis
GB201800736D0 (en) Combination therapy for treatment of leukemia
IL266993A (en) Combined therapy for cancer treatment
IL284162A (en) Integrated healing for cancer treatment
IL281997A (en) Combined treatment for the treatment of uveal melanoma
MX2017009632A (es) Tratamiento conjunto usando conjugado anticuerpo-farmaco dirigido a (cd-19) y vincristina.
IL279591A (en) Cancer treatment methods using combination therapy
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
IL281782A (en) Drug combination for cancer treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)